CD26 CAR-T cells have attenuated mitochondrial and glycolytic metabolic profiling

Xiaoying Zhu1,2,3, Zhaodong Zhong1, Fankai Meng4

  • 1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Abstract

Insights

Chimeric antigen receptor T (CAR-T) cells targeting CD26 exhibit unfavorable metabolic changes during expansion due to self-antigen stimulation. This impacts their persistence and function, suggesting a need for metabolic optimization strategies.

Area of Science:

  • Immunology
  • Cell Biology
  • Metabolic Engineering

Background:

  • Chimeric antigen receptor T (CAR-T) cells can be continuously stimulated by self-antigens shared between tumor and T cells.
  • Persistent antigen exposure can lead to metabolic reprogramming, influencing CAR-T cell fate and function.
  • The impact of self-antigen stimulation on CAR-T cell metabolic profiling during generation remains unclear.

Purpose of the Study:

  • To investigate the metabolic characteristics of CD26 CAR-T cells, which express the CD26 self-antigen.
  • To determine if self-antigen expression influences CAR-T cell metabolism and function.

Main Methods:

  • Evaluated mitochondrial biogenesis (content, mtDNA copy number, regulatory genes) in CD26 and CD19 CAR-T cells.
  • Assessed metabolic profiling via ATP production, mitochondrial quality, and metabolism-related gene expression.
  • Analyzed CAR-T cell phenotypes using memory-related markers.

Main Results:

  • CD26 CAR-T cells showed increased mitochondrial biogenesis, ATP production, and oxidative phosphorylation early in expansion.
  • At later stages, CD26 CAR-T cells exhibited weakened mitochondrial biogenesis, quality, oxidative phosphorylation, and glycolytic activity.
  • CD19 CAR-T cells did not display these metabolic alterations.

Conclusions:

  • CD26 CAR-T cells possess a distinct metabolic profile during expansion that is detrimental to their persistence and effector functions.
  • Findings offer insights for optimizing CD26 CAR-T cell metabolism for improved therapeutic outcomes.